Select Page

Media Release: Sight-saving treatment retained for Australians

RANZCO welcomes the move by both Australian major parties to reject a proposed Medicare rebate cut to sight saving treatment.

Since their introduction in Australia 15 years ago, sight-saving injections have revolutionised the management of multiple neovascular macular conditions. This treatment is non-curative, and it is essential that patients maintain regular injections to retain vision.

RANZCO applauds the Macular Disease Foundation Australia (MDFA) for its efforts in securing commitments from the government and opposition that a proposed Medicare rebate cut to sight saving treatment will not materialise.

Read more details in the media release.

Last updated: May 5, 2022

Get in Touch

Do you have any queries or comments about our website, our products or any  of our services?
RANZCO acknowledges our First Australians, the Traditional Custodians of the land
on which we live and work, and pays respect to Elders past, present and emerging.
Gadigal people of the Eora Nation are the traditional custodians of the land
where the RANZCO head office is located.
In recognition that we are a bi-national College, we also
acknowledge the Rangatiratanga of Māori as Tangata Whenua
and Treaty of Waitangi partners in Aotearoa New Zealand.